文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Mecasin治疗肌萎缩侧索硬化患者的随机对照试验研究方案

Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-04-13

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes paralysis of limb, swallowing, and breathing muscles.…

要点

  • Mecasin联合利鲁唑100 mg用于ALS患者,探索1.6 g与2.4 g两个剂量。
  • 主要终点为12周韩版ALS功能评分量表修订版(ALS FRS-R)结果。
  • 次要终点涵盖生活质量、肌力、疼痛、抑郁、疲劳、肺功能及安全性。

核心结论

  • 本试验旨在确定Mecasin的最佳剂量,并检验其联合利鲁唑标准治疗缓解ALS患者功能衰退的有效性与安全性。

主要发现

  • 原文为研究方案,未报告试验结果。

关键数值与推荐

  • 主要结局为治疗12周后韩版肌萎缩侧索硬化功能评分量表修订版(ALS FRS-R)结果。
  • 次要结局包括Short Form Health Survey-8、医学研究委员会肌力评分、疼痛视觉模拟评分、汉密尔顿抑郁评定量表、疲劳严重度量表、患者总体印象变化、肺功能测试、第1秒用力呼气容积及其与用力肺活量比值、肌酸激酶和体重。
  • 将描述并记录总不良事件和严重不良事件的发生频率。

临床怎么用

  • 若试验证实有效,Mecasin可作为利鲁唑标准治疗基础上的联合用药选项,但需待结果公布后确定剂量与适用人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes paralysis of limb, swallowing, and breathing muscles. Riluzole, the Food and Drug Administration-approved drug for ALS, provides minimal benefit, prolonging patient life by only 2-3 months. Previous studies have found a neuro-protective and anti-neuroinflammatory effect of Mecasin, with retrospective studies providing suggestive evidence for a beneficial effect of Mecasin. The aim of this study was to develop a protocol to determine the proper dosage of Mecasin. METHODS: This is a phase II-A, multi-center, randomized study with three arms. Thirty-six patients with ALS will be randomly assigned to one of three groups, each receiving the standard treatment with 100 mg of riluzole in addition to one of 1.6 g of Mecasin, 2.4 g of Mecasin, or a placebo. The Primary outcome is the Korean version of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised result after 12 weeks of treatment. Secondary outcomes include results of the Short Form Health Survey-8, Medical Research Council Scale, Visual Analogue Scale for Pain, Hamilton Rating Scale for Depression, Fatigue Severity Scale, Patient Global Impression of Change, pulmonary function test, forced expiratory volume in 1 s and its ratio to forced vital capacity, creatine kinase, and body weight. The frequencies of total adverse events and serious adverse events will be described and documented. The trial protocol has been approved by the Institutional Review Board of the Wonkwang University Gwangju and Sanbon Hospital (2016-5-4 and 2016-34-01, respectively). An Investigational New Drug status (30731) was granted by the Korea Food and Drug Administration. DISCUSSION: This trial will aim to identify the optimal dosage of Mecasin. Additionally, it will test the efficacy and safety of Mecasin in conjunction with standard treatment, riluzole, for alleviating the functional decline in patients with ALS. TRIAL REGISTRATION: Korean National Clinical Trial Registry CRIS; KCT0001984 . Registered on 28 July 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kim S, Kim JK, Son MJ, et al. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29653550. doi:10.1186/s13063-018-2557-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。